# [sPHT-1] [ 11/15/2007 (Thr) 10:30 - 11:00 / 2nd FL ]

## Metabolomic approach for evaluating drug response

### Byung Hwa Jung

### Bioanalysis and Biotransformation Research center

# Korea Institute of Science and Technology

#### Abstract

Metabolomics is an emerging technology which makes it possible to evaluate change of biological system in response to the physiological, environmental alterations. It has advantages in the simplicity and sensitivity to analyze metabolites since the researcher can use cutting edge instrument, such as mass spectrometry and simple sample preparation method compared to genomics or proteomics. Nowadays this technology has been tried in pharmaceutical area to investigate toxicity and efficacy of drug candidates and drugs in preclinical test. The metabolomic applications on the pharmaceutics for early prediction on toxicity and efficacy are described in this presentation. The multivariate analysis to get metabolic fingerprinting and its relations with the physiological changes are investigated with several drugs. Feasibility of metabolomic application for pharmaceutical area would be suggested from those researches.

Key word: metabolomics, drug, efficacy, toxicity, mass spectrometry

Generals on the metabolomics and its application to evaluate responses producing

by drug in biological system will be mentioned in this presentation.

Metabolomics is one of the "-omics" technology, which was ranked as one of the 10 emerging technologies by Technology Review (pressed by MIT), a massive research effort began in the mid-1990s and culminated after 2000.




Fig.1. OMIS cascade

Metabolites are the main object for metabolomics and they are generated through metabolism-all the chemical reactions within the body that create. They have small molecular weight below than 1000 and scientists can find unique patterns, or profiles by studying the changes and concentrations of these small metabolites within all kind of biological samples. These profiles change when the body is fighting a disease, reacting to a drug, or responding to another form of stress. So metabolomics can be defined as the evaluation of tissues and body fluids, such as urine, blood, plasma, saliva, and cerebrospinal fluid, for metabolite changes that may result from bodily responses.

Nowadays metabolomics was applied on the many field of life science. The bellows are representative application of metabolomics.

- To make safer drugs by predicting the potential for adverse effects (toxicity) earlier
- To target specific groups of people most likely to benefit from a drug, while excluding its use by those who may be harmed by it
- To speed the discovery and development of drugs
- To diagnose disease or predict the risk of disease
- To determine whether a treatment is working or not
- To monitor healthy people to detect early signs of disease.

Among the field mentioned above, it is quite challengeable to use metabolomics to investigate drug response, efficacy and toxicity since metabolite is the best compound to express phenotype which is appeared by drug treatment. Metabolite could be determined invasive all kind of biological samples like urine, hair by novel instrumental analysis and it response fast and researcher can detect it with very slight change of genetic or environmental change. Moreover it is cheaper and faster than any other —OMICS technologies.

With these advantages, metabolomics has been used recently to evaluate drug efficacy and toxicity.

Rodenburg R.J.T and colleagues (1) used metabolomics approach to evaluate action mechanism of anti-inflammatory compounds with score plot of lipid pattern (Fig.2).

In this research the lipid expression patterns of zilpaterol, salbutamol and clenbuterol are clustered together in the lower left corner. This result indicates a similarity in lipid expression pattern of the three  $\beta$ -agonists and it was suggested that those drugs clustered together might have similar action mechanism as anti inflammatory drugs.




Fig.2. Score plots of the lipid patterns of zilpaterol. Clenbuterol, salbutamol, SB203580, dexamethasone and protease inhibitors. (by Rodenburg RJT et al)

Recently, researches on the finding of metabolic biomarker for toxicity prediction has been increased, Keun HC et al showed multivariate patter recognition (Fig.3) to detect specific biomarker and time dependent process (2).

Nowadays metabolomics extends its area to the personalized medicine. Nicholson JK and his colleagues suggested that global approach of metabolomics could be a useful tool to investigate the integration of complex change and toxicity in biological system (3).

In our study, both of targeted and global metabolic profiling was used to elucidate biomarker and make clustering pattern with multivariate analysis for predicting drug efficacy/toxicity.

Korean herb decoction was tested if it has changed the ratio of dihydrogestosterone (DHT) and testosterone (T) by quantify urinary DHT and T. The feasibility of toxicity prediction was test using the drug with hepatotoxicity.

Those researches are the pilot study for the new field of metabolomics and lots of meaningful data is coming out nowadays. Metabolomics also has been used in the new drug development area, such as drug target identification, target validation, and clinical trials.




Fig.3. Metabolomic data analysis. (by Keun HC et al)

In conclusion, it is thought that metabolomics approach should be a useful tool to evaluate drug efficacy and toxicity and new drug development area, and its application on the pharmaceutical area could be extended in near future.

### References

- 1. Verhoeckx. KCM, Bijlsma S, Jespersen S, Ramaker R, Verheij ER Witkamp RF, van der Greef J, Rodenburg RJT. Characterization of anti-inflammatory compounds using transcriptomics, proteomics, and metabolomics in combination with multivariate analysis. Int. Immunopharmacol. 2, 1499-1514 (2004).
- 2. Keun HC. Metabolomic modeling of drug toxicity. Pharmacol. Ther. 109, 92-106 (2006).
- Clayton TA, Lindon JC, Clorec O, Antti H, Charuel C, Hanton G, Provost JP, Le Net J, Baker D, Walley RJ, Everett JR, Nichoson JK. Pharmacometabolomic phenotyping and personalized drug treatment. Nature 440, 1073-1077 (2006).